focus -WSS

focus

author：focus 2025-09-27 22:46:53 - browse：43

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare drug price lawsuits could be good politics for Biden

knowledge

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

The thinking behind the controversial eating disorder chatbot Tessa

FDA approves first new drug developed for postpartum depression

Cardiologists urge adding sexual orientation, gender identity to health records

Medicare bonuses could stop drug shortages under Senate plan

Sea level rise could wash away turtle breeding grounds around the world, researchers say

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

In age of alternative facts, a scholarly course on calling out crap

Cardiologists urge adding sexual orientation, gender identity to health records

BioMarin wins approval for gene therapy to treat hemophilia A

Mom launches Girl Scout troop for LGBTQ youth in Texas

United colonoscopy coverage change 'may cost lives,' doctors say

FDA endorses new sterilization method for medical devices

In age of alternative facts, a scholarly course on calling out crap

HPV vaccine, cervical cancer study delivers historic results

Medical records are filled with copy

FDA endorses new sterilization method for medical devices

leisure time

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Head of FDA's diagnostics center, who led through Covid, retires

Mom launches Girl Scout troop for LGBTQ youth in Texas

Printout prescription drug information shouldn’t go digital

FDA endorses new sterilization method for medical devices

CVS is on a mission to consolidate health care. Will it work?

hotspot

knowledge

entertainment

knowledge